← Eichor
Study identifier: NCT07137364 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism

Condition: Primary Aldosteronism · Hypertension  ·  Sponsor: Third Military Medical University

PhaseN/A
Planned participants350
Who can joinAll sexes, 30 Years to 65 Years
Healthy volunteersNo

About this study

The goal of this observational study is to learn about the optimal dose of spironolactone treatment and the long-term outcomes on cardiovascular and cerebrovascular events in patients with lateralized PA who are unwilling to undergo surgery. The main question it aims to answer is: 1. What is the long-term effect of spironolactone treatment for lateralized PA? 2. What is the optimal dose of spironolactone treatment for the relief of renin inhibition in patients with lateralized PA? Participants will receive spironolactone treatment as part of their regular medical care for more than 12 months, and their clinical indicators, including blood pressure, biochemical remission, cardiovascular and renal damage, and the incidence of cardiovascular and cerebrovascular events, will be analyzed.

This description comes directly from the study's public registry record.

Talk to the study team

Zhencheng Yan, MD  ·  +8613983656682  ·  zhenchengyan@sina.com

Always discuss trial participation with your own doctor first.

Locations (1)

Daping Hospital, Army Medical Center of PLAChongqing, Chongqing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07137364